Supplementary Tables. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations..docx

Supplementary Tables. Co-stimulatory and co-inhibitory immune
markers in solid tumors with MET alterations.

Background

The
implication of MET alterations in solid tumors and the immune
microenvironment remains elusive.

Materials
& Methods

FFPE
samples of 21 patients with solid tumors harboring MET alterations were used
for IHC staining. Extracted RNA was analyzed with the NanoString nCounter
human PanCancer Immune Profiling Panel.

Results

Patients
were diagnosed with lung (N=10), breast (N=5), genitourinary (N=3), or
colorectal cancer (N=3). Eleven had a MET missense mutation, 4 had an exon 14
splice site mutation, and 6 had MET amplification. CD6, CCL19, ATM, CD40LG,
XCR1, MAGEA1, ATM and CCL19 genes were significantly differentially expressed
in MET-altered cancers.

Conclusion

MET alterations may have a role in various solid
tumors as potential therapeutic targets and combination therapy candidates with
immune checkpoint inhibitors.